

ASX ANNOUNCEMENT

12 JULY 2022

LGP SIGNS ~\$2M SUPPLY AGREEMENT WITH ILIOS SANTÉ



Highlights:

- LGP signs two-year ~\$2 million medicinal cannabis supply agreement with Ilios Santé in Germany
- Ilios Santé to purchase minimum annual quantities of a high-THC white-label medicinal cannabis flower product being developed by LGP
- Ilios Santé is a licensed pharmaceutical wholesaler headquartered in Frankfurt and wholly-owned subsidiary of The Bloomwell Group, a leading European medical cannabis healthcare company
- The Agreement represents continued validation of LGP's key strategy of developing bespoke, high-value white label strains for export to lucrative jurisdictions, and further consolidates LGP's growing industry reputation as one of the leading global pure-play medicinal cannabis suppliers operating in Europe

Little Green Pharma Ltd (ASX: LGP, "**LGP**" or the "**Company**") is pleased to announce its entry into an agreement with Frankfurt-headquartered and licenced pharmaceutical wholesaler, Ilios Santé GmbH ("**Ilios Santé**") for the supply of a non-exclusive LGP white label medicinal cannabis product into Germany ("**Agreement**").

The Agreement highlights the continued success of LGP's extensive genetics program which has resulted in a world-class bank of cannabis cultivars including over 20 strains in various stages of development.

The Agreement is a welcome addition to LGP's rapidly expanding suite of high-value supply agreements from its Danish Facility into the EU, joining agreements with AMP, Demecan and Four 20 Pharma in Germany (see ASX announcements dated 19 January, 19 April and 19 May 2022 respectively) with an aggregate potential value of ~\$35 million¹ over three years. These agreements represent the fruition of LGP's strategy of producing large-volume bespoke strain white-label products for supply into Europe and the UK while servicing these markets with its own, LGP branded products. The Agreement also consolidates LGP's growing industry reputation as one of the leading global pure-play medicinal cannabis suppliers operating in Europe.

¹ Assumes satisfaction of minimum exclusivity purchase, minimum annual quantity and take or pay commitments

Material terms of the Agreement

- The Agreement is ex-works and for the supply of a non-exclusive high-THC white-label product being developed at LGP's Denmark Facilities
- The supply period is for two years starting from delivery of the first shipment. The product may be supplied in final or bulk packaged form, with pricing fixed and tiered according to finished form and ordered quantities in each quarter
- Based on the minimum annual quantities to be purchased by Ilios Santé during the two-year term, the Agreement has a value of ~\$2 million (~€1.4 million², with ~80% of the minimum quantities falling in the second year. Ilios Santé must place minimum orders of 20kg per shipment after the first 6 months
- Supply of the product is subject to certain conditions precedent relating to approvals for distribution in the territory and entry into a GMP Quality Agreement, as well as the product meeting a minimum shelf life
- The timing of first shipment will depend on Ilios Santé election to take irradiated or non-irradiated product, with irradiated product requiring an additional licence from German regulatory authorities. LGP expects non-irradiated product to be available for delivery in the current quarter
- LGP may terminate the Agreement if its cost of production exceeds the minimum product purchase price.

About Ilios Santé & The Bloomwell Group

Ilios Santé is an EU Good Distribution Practices (**GDP**) licensed pharmaceutical wholesaler headquartered in Frankfurt, Germany and a wholly-owned subsidiary of leading German medical cannabis healthcare company, The Bloomwell Group.

The Bloomwell Group is a holding company for medical cannabis companies with a mission to build, acquire and invest in ESG healthcare companies along the entire value chain outside of cultivation.


As part of the Bloomwell Group, Ilios Santé is part of a fully integrated group of distinct cannabis-related brands, each fulfilling a different purpose, including Ilios Santé in the medicinal cannabis space, Algea Care, Europe's leading telemedicine platform, and Bloomwell's lifestyle brand, Breezy.

Commenting on the Agreement, Little Green Pharma Chief Executive Officer, Fleta Solomon, said:

"This partnership with Ilios Santé is very exciting as it not only strengthens our share of the medicinal cannabis product market in Germany but at the same time strategically partners us with The Bloomwell Group, a European leader in medical cannabis groups operating along the entire value chain. We look forward to collaborating with Ilios Santé to help service our rapidly growing number of medicinal cannabis patients in Germany."

² EUR: AUD 0.673 (as at 8 July 2022)

ENDS
BY ORDER OF THE BOARD


Alistair Warren
Company Secretary



For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +618 6280 0050

Fleta Solomon
Chief Executive Officer
Little Green Pharma
E: f.solomon@lgp.global
T: +618 6280 0050

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m² cultivation and 4,000m² GMP manufacturing facility capable of producing over 30 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp